Hydrate forms of AMG706

Details Hydrate forms of AMG706 Hydrate forms of AMG706

2011-08-02

2011-08-02

Morris, Patricia L (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07989631

ABSTRACT:
The anti-angiogenic drug AMG 706 is provided in the mono-phosphate hydrate form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as AMG 706 phosphate dihydrate. Also provided are processes for preparing AMG 706 phosphate dihydrate, AMG 706 drug substance of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with an anti-angiogenic is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.

REFERENCES:
patent: 5990141 (1999-11-01), Hirth et al.
patent: 6001961 (1999-12-01), Jonczyk et al.
patent: 6235764 (2001-05-01), Larson et al.
patent: 6258812 (2001-07-01), Bold et al.
patent: 6627646 (2003-09-01), Bakale et al.
patent: 6878714 (2005-04-01), Askew et al.
patent: 6995162 (2006-02-01), Chen et al.
patent: 0 407 122 (1991-01-01), None
patent: 0 970 070 (2004-10-01), None
patent: 02233610 (1990-09-01), None
patent: 99/45009 (1999-09-01), None
patent: 99/61422 (1999-12-01), None
patent: 00/02871 (2000-01-01), None
patent: 00/12089 (2000-03-01), None
patent: 00/59509 (2000-10-01), None
patent: 01/32651 (2001-05-01), None
patent: 01/37820 (2001-05-01), None
patent: 02/055501 (2002-07-01), None
patent: 02/059110 (2002-08-01), None
patent: 02/066470 (2002-08-01), None
patent: 02/068406 (2002-09-01), None
patent: 2004/005279 (2004-01-01), None
patent: 2004/007458 (2004-01-01), None
patent: 2004/007481 (2004-01-01), None
patent: 2004/009784 (2004-01-01), None
Chemical & Engineering News, Feb. 2003, 32-35.
Brittain et al., “Polymorphism in Pharmaceutical, etc., ”NY: Marcel Dekker, Inc., 1999, 1-2, 125-181,183-226.
US Pharmacopia #23, National Formulary #18 (1995), 1843-1844.
Vippagunta et al., “Crystalline Solids”, Advanced Drug Delivery Reviews 48 (2001) 3-26.
Doelker, “Physiochemical behavior, etc.,” S.T.P. Pharma Pratiques (1999), 9(5), 399-409 and english translation pp. 1-39.
CMU Pharmaceutical polymorphism, intenet p. 1-3 (2002) (printout Apr. 3, 2008).
Singhal et al., “Drug polymorphism, etc., ”Advanced drug delivery reviews 56, 335-347 (2004).
Caira, “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, 198, Berlin Heidlberg: Spring Verlag 1998, 184-208.
Muzaffar et al., Polymorphism and Drug Availability, etc., J of Pharm. (Lahore), 1979, 1(1), 59-66.
Jain et al., “Polymorphism in Pharmacy”, Indian Drugs, 1986, 23(6), 315-329.
Taday et al., “Using Terahertz, etc.,” J. of Pharm. Sci.., 92(4), 2003, 831-838.
Otsuka et al., “Effect of Polymorphis Forms, etc.,” Chem. Pharm. Bull. 47(6) 852-856 (1999).
Ovid Copyright #2013210, “R & D Focus”, Drug Name, Motesanib, (2004).
Bush, et al., “Anti-tumor Activity of Motesanib Diphosphate Alone and in Combination with Docetaxel or Tamoxifen in Xenograft Models of Human Breast Carcinome”, Breast Can. Res. And Treatment, 106(1):S77 (2007).
Milano, et al., “New Molecular Targeted Therapies in Thyroid Cancer”, Anti-Cancer Drugs, 17(8):869-879 (2006).
Polverino, et al., “AMG 706, an Oral Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts”, Can. Res., 66(77):8715-8721 (2006).
Rosen, et al., “Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients with Advanced Solid Tumors”, J. of Clin. Oncology, 25)17): 2369-2376 (2007).
Sherman, et al., “Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer”, New England J. of Medicine, 359(1):31-42 (2008).
Sorbera, et al., Oncolytic Antiangiogenic Agent Multikinase Inhibitor, Drugs of the Future, 31(10):847-853 (2006).
Wadke, et al., “Pharmaceutical Dosage Forms”, 2nd Edition, ed. Herbert A. Lieberman, Published by Marcel Dekker, New York, 1:34-36 (1989).
Ovid Copyright #11016, “R & D Insight”, Drug Name, Motesanib, (2003).
Ovid Copyright #037998, “Pharmaprojects”, Drug Name, Motesanib Diphosphate, (2007).

Affiliated with

Also associated with

Rating

Hydrate forms of AMG706 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydrate forms of AMG706, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrate forms of AMG706 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2661354